MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-19-2024
Talis Biomedical Corporation Accounts Receivables 2011-2026 | TLIS
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Talis Biomedical Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50 K | 308 K | 183 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 308 K | 50 K | 180 K |
Quarterly Accounts Receivables Talis Biomedical Corporation
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 6 K | 50 K | 5 K | 532 K | 127 K | 308 K | 433 K | - | 2.6 M | 183 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.6 M | 5 K | 471 K |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
128 K | $ 2.2 | 2.8 % | $ 3.43 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 10.49 | 0.62 % | $ 1.42 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Butterfly Network
BFLY
|
20.8 M | $ 4.17 | 6.52 % | $ 883 M | USA |
 |
Alphatec Holdings
ATEC
|
97.3 M | $ 12.8 | 1.59 % | $ 1.92 B | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
175 M | $ 8.38 | - | $ 602 M |  Israel |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 37.12 | -0.78 % | $ 1.15 B | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.69 | 6.49 % | $ 37.6 M | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.05 | 2.27 % | $ 151 M |  France |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | USA |
 |
Establishment Labs Holdings
ESTA
|
77.5 M | $ 64.57 | 1.72 % | $ 1.91 B |  Costa-rica |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
ClearPoint Neuro
CLPT
|
4.71 M | $ 11.11 | 0.73 % | $ 300 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Helius Medical Technologies
HSDT
|
117 K | $ 2.21 | 0.68 % | $ 1.34 M | USA |
 |
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | USA |
 |
InMode Ltd.
INMD
|
10.5 M | $ 13.49 | 0.45 % | $ 872 M | Israel |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.31 | -1.5 % | $ 21.1 M | USA |
 |
Abbott Laboratories
ABT
|
7.93 B | $ 111.25 | 1.18 % | $ 194 B | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 9.79 | -0.2 % | $ 351 M | USA |
 |
Bio-Rad Laboratories
BIO
|
452 M | $ 269.09 | 3.0 % | $ 7.59 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 9.18 | 1.89 % | $ 707 M | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 62.56 | 1.83 % | $ 3.41 B |  Britain |
 |
AxoGen
AXGN
|
26.2 M | $ 32.76 | -0.24 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
996 M | $ 176.5 | 4.16 % | $ 13.2 B | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 33.7 | 2.87 % | $ 5.02 K | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
16.8 M | $ 3.75 | 2.18 % | $ 154 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 17.1 | -0.06 % | $ 401 M | USA |
 |
MiMedx Group
MDXG
|
75.7 M | $ 4.45 | 0.79 % | $ 658 M | USA |
 |
Integer Holdings Corporation
ITGR
|
346 M | $ 86.36 | 2.66 % | $ 3 B | USA |